Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Bellido V, le Roux CW, Ekinci EI, et al. The Lancet 2026;408:1455-1472.
What it found
Mean weight change of -11.9% (4 mg), -16.8% (9 mg) and -18.8% (12 mg) vs -5.1% with placebo. Diarrhoea (27-34% vs 13%) and nausea (14-28% vs 8%) were more common on retatrutide, as were low blood pressure (up to 6% vs under 1%) and dysaesthesia, an abnormal skin sensation (4-7% vs 1%). Stopping because of side effects or death: 12% on 9 mg and 8% on 12 mg vs 5% on placebo.
Limitations
Weight loss was smaller than in people without diabetes. 80 weeks; longer-term safety and outcome data are not yet available. Funded and run by the developer.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.